Additionally, for patients with T2DM treated with SGLT2i, lower levels of plasminogen activator inhibitor-1 (PAI1) have been observed, which may help to deter thrombosis and stabilize plaque, further explaining the cardiovascular protection provided by SGLT2i [77]. The gene discussed is SERPINE1; the disease is type 2 diabetes mellitus.